Introduction: Tumor Heterogeneity and Current Challenges in Triple-Negative Breast Cancer (TNBC) Treatment {#S1}
==========================================================================================================

Breast cancer is the most frequently diagnosed cancer among women in the United States and Europe ([@B1], [@B2]). Despite the relative improvement in patient survival rates, breast cancer remains the most commonly diagnosed cancer and the second leading cause of cancer deaths in women worldwide. One of major challenges for the effective treatment of breast cancer is its intertumoral and intratumoral heterogeneity ([@B3]). Breast cancer can be initially classified into three different types based on the presence or absence of estrogen receptors (ERs), progesterone receptors (PRs), and the human epidermal growth factor receptor 2 (Her2/neu) ([@B4]). Hormone receptor-positive breast cancers that express ER and/or PR constitute approximately 60% of all breast cancers ([@B5]). The Her2/neu receptor is overexpressed in approximately 20% of all breast cancer cases; while TNBC constitute approximately 20% of breast cancer cases and are negative for the expression of ER, PR, and Her2/neu ([@B6], [@B7]).

Based on their molecular profile, breast cancers may also be clustered into basal-like and luminal subsets. Luminal breast cancers are more heterogeneous compared to basal cancers in terms of gene expression, mutation spectrum, copy number changes, and patient outcomes and can be further subdivided into luminal A and B subtypes ([@B8], [@B9]). The luminal A subtype represents 50--60% of breast cancer cases and is characterized by low histological grade and good prognosis. Luminal A cancers express ER and PR and have a low frequency of P53 mutations ([@B9]). Luminal B represents 10--20% of all breast cancers; compared with the luminal A subtype, these cancers are more aggressive; they have a higher grade, worse prognosis, and worse proliferative index. Luminal B display an increased expression of proliferation genes; they are ER+, PR+/−, Her-2+/−, and EGFR+ and have a higher frequency of P53 mutation ([@B9]). Because luminal cancers have a high frequency of PIK~3~CA mutations, the gene that encodes the p110α catalytic subunit of the phosphatidylinositol 3-kinase (PI~3~K), agents targeting the PI~3~K/AKT/mammalian target of rapamycin pathway may be useful for their treatment ([@B10]).

The basal-like subtype represents 10--20% of breast cancer cases. They are characterized by high proliferation, high histological grade, and poor prognosis. Basal-like cancers can be triple negative and have a high frequency of P53 mutations combined with loss of Rb1 ([@B9], [@B11]). However, not all basal-like cancers are triple negative; studies have shown that 5--45% of basal-like cancers express ER while 14% express Her2/Neu ([@B12], [@B13]). TNBC is a diverse group of malignancies and can be further categorized to different subtypes. An analysis of 21 breast cancer data sets containing 587 TNBC cases identified seven subtypes based on differential expression of a set of 2,188 genes: two basal like (BL1 and BL2), a mesenchymal (M), a mesenchymal-stem cell-like, an immunomodulatory, a luminal androgen receptor/luminal-like, and an unclassified type ([@B14]).

The deregulation of adult mammary stem cells (aMaSC) during tumorigenesis is believed to contribute to the development of TNBC. aMaSCs give rise to common progenitor cells that can differentiate either to basal progenitors that develop mature basal cells, or luminal progenitors. Disruption in the homeostasis of luminal progenitor cells may lead to the development of TNBC. Contributors in the development of TNBC include aberrantly activated signaling pathways, such as Wnt/β-catenin and Notch, transcriptional factors, like Snail, and embryonic stem cell markers including Sox2, Nanog, and Oct4. These alterations allow the restoration of proliferation capacity as well as the de-differentiation of these progenitor cells, leading to the accumulation of mutations that give rise to TNBC ([@B15]).

Traditionally, due to the lack of ER, PR, and Her2/Neu expression, the ineffectiveness of current breast cancer targeted therapies as well as due to the challenges in identifying key molecular drivers of TNBC progression, chemotherapy has been the foundation of treatment for patients with this disease over the last decades. Despite its sensitivity to chemotherapy, TNBC is associated with a higher risk of distant recurrence, high rates of metastases, higher probability of relapse and worse overall survival (OS) compared to other subtypes ([@B16], [@B17]).

Complexity of TNBC Metastasis {#S2}
=============================

The dissemination of breast cancer cells and eventual metastatic growth to distant organs---predominantly the bone, lungs, and brain---represents a significant clinical problem, as metastatic disease is incurable and is the primary cause of death for the vast majority of TNBC patients. Metastatic spread of tumor cells is a highly complex, yet poorly understood process, and consists of multiple steps, including acquisition of invasive properties through genetic and epigenetic alterations, angiogenesis, tumor--stroma interactions, intravasation through the basement membrane, survival in the circulation, and extravasation of some cancer cells to distal tissues ([@B18]). However, disseminated cells that survive pro-apoptotic signals in their new environment often remain quiescent in secondary organs undergoing long periods of latency, also known as the dormancy period ([@B19]). It is well established that the outgrowth of metastatic cells in a foreign tissue microenvironment is a highly inefficient process and is considered as the rate-limiting step of breast cancer metastasis ([@B20]) (Figure [1](#F1){ref-type="fig"}). During this stage, breast cancer cells are usually difficult to detect and exhibit resistance to chemotherapy due to lack of proliferation ([@B19]). This remains a major clinical problem since patients, often considered as "survivors," can develop metastatic disease years later. Disseminated tumor cells (DTCs) can enter a state of dormancy in secondary organs by exiting the proliferative cycle for an indefinite period or by achieving a balanced state of proliferation and apoptosis. Successful emergence from dormancy is the result of further evolution of surviving DTCs, by accumulating molecular alterations as well as *via* permissive interactions with the tumor microenvironment ([@B19]). By acquiring these characteristics, metastatic populations can optimally adapt to the host microenvironment and initiate colonization. While significant progress has been made to highlight some of the specific processes required for the breast tumor initiation, efforts have recently been focused on elucidating the roles of critical genes, the underlying molecular mechanisms and signaling pathways involved in the fatal late stages of metastatic dissemination. These studies are of outmost importance for the development of novel effective treatments against metastasis of TNBC.

![A model for the molecular basis of triple-negative breast cancer. During local invasion and intravasation, an epithelial-to-mesenchymal transition (EMT) transcriptional program is initiated along with the activation of matrix metalloproteases and pro-migratory signaling. Upon entering the circulation, breast cancer cells can interact with platelets, enable pro-survival pathways to suppress anoikis, and resist apoptotic signals. Then, migrated cancer cells extravasate through the endothelial blood vessel wall to a secondary organ where they enter a prolonged dormant state by forming micrometastases. Finally, the activation of metastasis-colonizing genes and the interaction with the local microenvironment create permissive conditions for macrometastatic outgrowth. Red: metastasis promoters, green: metastasis suppressors.](fonc-08-00031-g001){#F1}

Genes Implicated in Multistep TNBC Metastasis {#S3}
=============================================

Local Invasion/Intravasation {#S3-1}
----------------------------

Upon accumulation of genetic and/or epigenetic alterations, breast cancer cells at the primary tumor initially acquire properties, such as self-renewal, ability to migrate, and invade the surrounding normal tissues. During local invasion, breast cancer cells undergo epithelial-to-mesenchymal transition (EMT), a highly orchestrated transcriptional program, initially described during embryonic development, associated with dramatic remodeling of cytoskeleton, loss of apico-basolateral polarity, dissolution of cell--cell junctions, concomitant with downregulation of epithelial markers and upregulation of mesenchymal genes ([@B21]). This process is triggered by EMT-master regulators, such as the transcription factors Slug, Snail, and Twist to promote TNBC cell migration and intravasation in the circulation ([@B22]--[@B24]). The TGFβ pathway plays a critical role in regulating this early metastatic event. During intravasation, TGFβ promotes overexpression of musculoaponeurotic fibrosarcoma oncogene family protein K (MAFK) to induce EMT and enhance tumor formation and invasion *in vivo* ([@B25]). The TGFβ-Smad signaling axis controls the EMT step in the malignant progression of breast cancer cells either by inducing the expression of master transcriptional regulators of EMT, as described above, or by epigenetic silencing of epithelial genes, including CDH1 ([@B26]). The EMT program regulated by TGFβ/Smad signaling also involves WAVE3, a WASP/WAVE family actin-binding protein. In TNBC cells, depletion of WAVE3 expression prevented TGFβ-induced EMT phenotype ([@B27]). However, despite numerous studies using cell lines and animal models suggesting a functional role of EMT and EMT-inducing transcription factors in promoting breast cancer metastasis, the *in vivo* role and clinical relevance of this process remains controversial ([@B28]--[@B31]).

Moreover, the majority of genes implicated in TNBC metastasis have been reported to play a major role at the initial stages of cancer cell dissemination which include migration, invasion, and intravasation. This is not surprising given the fact that cancer cell dissemination is thought to be an early event during breast cancer evolution and that primary and metastatic tumor growth is likely to progress in parallel ([@B32]). For example, activation of CXCR4 receptor *via* its ligand CXCL12 or ANGPTL2 was found to induce MLK3 and Erk1/2 signaling and promote intravasation which leads to the development of lung and bone metastases ([@B33]--[@B39]). This hyperactive signaling axis may also function in multiple stages of the metastatic cascade, including angiogenesis, extravasation, and osteolysis at the secondary organ. At the same time, it is becoming increasingly clear that trans-endothelial migration and invasion of breast cancer cells in the vasculature is inhibited by metastasis suppressors, including TP63, LIFR, lysyl oxidase-like 4 (LOXL4), FOXF2, SSBP1, RAB1B, and TIEG1 ([@B25], [@B40]--[@B47]), suggesting that the migratory and invasive potential of breast cancer cells is ultimately determined by the balance in the activity of these molecules. The identification of numerous genes implicated in the initial stages of TNBC metastasis highlights the significant challenges for early molecular diagnosis and therapy.

Survival in Circulation {#S3-2}
-----------------------

Upon entering the blood vessels, circulating tumor cells express proteins that have antiapoptotic and pro-survival functions which allow them to attach to and infiltrate specific secondary sites. Neurotrophic tyrosine kinase receptor TRKB was shown to inhibit anoikis, a form of cell death caused by lack of adhesion, *via* the PI~3~K/Akt pathway. These studies indicated that TRKB induces survival and proliferation of breast cancer cells to promote infiltration in the lymphatic and blood vessels and colonization in distant organs ([@B48]). In TNBC cells, brain-derived neurotrophic factor (BDNF) binds and activates TRKB receptor to regulate a network consisting of metalloproteases and calmodulin and thus modulate cancer--endothelial cells interaction. Importantly, Erk1/2 inhibitors were able to block the BDNF-induced phenotype, suggesting that blocking this pathway may be explored for therapeutic purposes against TNBC metastasis ([@B49]). In addition, the binding of platelets with circulating breast cancer cells has been shown to essential for their survival, evasion of pro-apoptotic signals, whereas interfering with this interaction inhibits the development of lung metastasis in TNBC mouse models ([@B50], [@B51]).

Extravasation in Distal Sites {#S3-3}
-----------------------------

Many of the genetic alterations found to be involved in intravasation are also implicated in extravasation (Table [1](#T1){ref-type="table"}) since, in large part, these two processes are considered "mirrored" to each other. The TGFβ pathway plays an important role in regulating both these metastatic steps. More specifically, TGFβ induces the assembly of a mutant-p53/Smad protein complex to inhibit the function of the metastasis suppressor TP63 and promote cell migration and invasion ([@B40]). During extravasation, TGFβ induces angiopoietin-like 4 (ANGPTL4) expression *via* the Smad signaling pathway; the increased levels of ANGPTL4 enhance the retention of cancer cells in the lungs by disrupting vascular endothelial cell--cell junctions, thus increasing the permeability of lung capillaries to facilitate trans-endothelial passage of breast cancer cells ([@B52]). Moreover, targeting the decoy interleukin-13 receptor alpha 2 (IL13Ra2) upregulates the metastasis suppressor TP63 in an IL13-mediated, STAT6-dependent manner and impairs extravasation of basal-like breast cancer cells to the lungs ([@B41]). Several reports also highlight the importance of the synergistic effects of genes in promoting metastasis by regulating specific stages of the process. For example, EREG, COX2, MMP1, and MMP2 can collectively promote metastatic extravasation to the lungs. These four genes were found to be overexpressed in TNBC cells independently of VEGF. Individual reduction of each gene or their silencing in different combinations produced limited effects on tumor growth *in vivo* while concurrent silencing of all four achieved nearly complete growth abrogation ([@B53]).

###### 

List of genes involved triple-negative breast cancer metastasis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Metastasis-promoting genes                                                                                                                                                                                                                                                                                                                                                                          
  --------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------ -------- ----------------------------
  ANGPTL2                           Promotes osteolysis\                                                                           Activates CXCR4 and Erk1/2 signaling                                                           Receptor binding, extracellular space                                                               Intravasation, extravasation\                          Bone     ([@B37])
                                    Migration\                                                                                                                                                                                                                                                                                        Angiogenesis\                                                   
                                    Angiogenesis                                                                                                                                                                                                                                                                                      Micro- to macrometastasis colonization                          

  ANGPTL4                           Promotes trans-endothelial cancer cell migration by disrupting lung capillary cell junctions   Activated by TGFβ signaling                                                                    Angiogenesis                                                                                        Extravasation                                          Lungs    ([@B52])

  CDCP1                             Reduces lipid droplets, stimulates fatty acid oxidization and oxidative phosphorylation        Interacts with and inhibits acyl-CoA-synthetase ligase                                         Plasma membrane, protein binding                                                                    Intravasation, extravasation\                          Lungs    ([@B54])
                                                                                                                                                                                                                                                                                                                                      Metastatic colonization and growth                              

  COX2                              Migration, invasion\                                                                           Mediates TGFβ-induced cancer cell stemness                                                     Prostaglandin biosynthetic process, angiogenesis                                                    Intravasation, extravasation\                          Bone     ([@B53], [@B55]--[@B57])
                                    Promotes cancer stem cell maintenance                                                                                                                                                                                                                                                             Self-renewal                                                    

  CSF2                              Osteoclast activation                                                                          Activated by NFκB signaling                                                                    Granulocyte macrophage colony-stimulating factor receptor binding                                   Micro- to macrometastasis colonization                 Bone     ([@B58])

  CXCL1/2                           Recruitment of myeloid cells                                                                   Activated by tumor necrosis factor-α/NFκB pathway                                              Receptor binding, extracellular region                                                              Cancer cell survival at primary and metastatic sites   Lungs    ([@B59], [@B60])

  CXCL12                            Binds CXCR4 to initiate downstream signaling                                                   Activates CXCR4 signaling                                                                      Response to hypoxia, migration, endothelial cell proliferation, receptor binding                    Intravasation, extravasation\                          Lungs    ([@B34])
                                                                                                                                                                                                                                                                                                                                      Angiogenesis                                                    

  CXCR4                             Mediates actin polymerization and formation of lamellopodia\                                   Activated by ANGPTL2                                                                           Activation of MAPK activity, response to hypoxia, chemotaxis, G-protein coupled receptor activity   Intravasation, extravasation\                          Lungs    ([@B33]--[@B36])
                                    Migration,\                                                                                                                                                                                                                                                                                       Angiogenesis                                                    
                                    Invasion\                                                                                                                                                                                                                                                                                                                                                         
                                    Angiogenesis                                                                                                                                                                                                                                                                                                                                                      

  CYR61                             Vascularization                                                                                Activated by Sonic-Hedgehog/Gli1 signaling                                                     Regulation of cell growth, angiogenesis                                                             Angiogenesis\                                          Lungs    ([@B61])
                                                                                                                                                                                                                                                                                                                                      Micro- to macrometastasis colonization                          

  EREG                              Promotes vessel remodeling and invasion                                                        VEGF-independent                                                                               MAPK cascade, angiogenesis                                                                          Intravasation\                                         Lungs    ([@B53])
                                                                                                                                                                                                                                                                                                                                      Extravasation\                                                  
                                                                                                                                                                                                                                                                                                                                      Angiogenesis                                                    

  FGFR                              Suppresses apoptosis and promotes survival                                                     Activates PI~3~K/Akt signaling                                                                 MAPK cascade, angiogenesis                                                                          Survival\                                              Lungs    ([@B62])
                                                                                                                                                                                                                                                                                                                                      Primary tumor growth\                                           
                                                                                                                                                                                                                                                                                                                                      Micro- to macrometastasis colonization                          

  FSCN                              Migration, invasion                                                                            Activates NFκB signaling\                                                                      Stress fiber, podosome, actin binding                                                               Intravasation, extravasation                           Lungs    ([@B63], [@B64])
                                                                                                                                   Increases MMP2, MMP9 expression                                                                                                                                                                                                                                    

  ID1, ID3                          Promotes tumor re-initiation                                                                   Induced by NFκB-mediated IGF2/PI~3~K signaling                                                 DNA binding transcription factor activity, angiogenesis                                             Micro- to macrometastasis colonization                 Lungs    ([@B65]--[@B67])

  IL13Ra2                           Migration                                                                                      Suppresses IL13--STAT6--P63 signaling                                                          Cytokine receptor activity, signal transducer activity                                              Extravasation                                          Lungs    ([@B41], [@B60])

  IRAK1                             Invasion\                                                                                      Activates NFκB and p38 signaling                                                               Activation of MAPK activity, regulation of cytokine-mediated signaling                              Intravasation, extravasation\                          Lungs    ([@B68])
                                    Promotes cancer stem cell maintenance                                                                                                                                                                                                                                                             Self-renewal                                                    

  LDH                               Catalyzes final reactions of glycolysis                                                        Activates glycolytic pathway                                                                   Response to hypoxia, lactate dehydrogenase activity, lactate/pyruvate metabolism                    Metastatic growth and colonization                     Brain    ([@B69], [@B70])

  LPA                               Produced by platelets to promote osteolysis                                                    Induces interleukin-6 and IL8 secretion by breast cancer cells                                 Fibronectin binding, endopeptidase activity                                                         Micro- to macrometastasis colonization                 Bone     ([@B71])

  MAFK                              Promotes epithelial-to-mesenchymal transition (EMT)                                            Activated by TGFβ pathway                                                                      DNA binding transcription factor activity                                                           Intravasation, extravasation                           Lungs    ([@B72])

  MLK3                              Drives invasion and trans-endothelial migration                                                Mediates CXCL12/CXCR4 signaling to promote paxillin phosphorylation\                           Activation of MAPK activity, protein serine/threonine kinase activity                               Intravasation\                                         Lungs    ([@B38], [@B39])
                                                                                                                                   Increases FRA1, MMP1 and MMP9 levels                                                                                                                                                               Extravasation                                                   

  MYOF                              Regulates lipid metabolism and mitochondrial function and promotes vesicle trafficking         Loss of MYOF suppresses AMPK phosphorylation and HIF1α stabilization due to metabolic stress   Phospholipid binding, plasma membrane, caveola                                                      Metastatic growth and colonization                     Lungs    ([@B73])

  NOS                               Promotes EMT, self-renewal, migration, invasion                                                Activates TGFβ and hypoxia signaling                                                           Response to hypoxia, nitric-oxide synthase activity                                                 Intravasation, extravasation\                          Lungs    ([@B74])
                                                                                                                                                                                                                                                                                                                                      Self-renewal                                                    

  NOTCH1/NOTCH2                     Migration, invasion\                                                                           Activate Notch signaling                                                                       Golgi membrane, cell fate determination, receptor activity                                          Intravasation, extravasation\                          Lungs\   ([@B75])
                                    Promotes cancer stem cell maintenance                                                                                                                                                                                                                                                             Tumor initiation and self-renewal                      Bone     

  OPN                               Mediates MSC-to-cancer-associated fibroblast transformation, tumor growth and invasion         Mediate TGFβ1 signaling to increase MMP2 and uPA levels                                        Osteoblast differentiation, cytokine activity                                                       Tumor growth Invasion                                  Lung\    ([@B76], [@B77])
                                                                                                                                                                                                                                                                                                                                                                                             Liver    

  PCDH7/CX43                        Promotes cancer cell-astrocyte interaction                                                     Activates IFNγ, NFκB pathway                                                                   Calcium ion binding, plasma membrane, cell adhesion                                                 Micro- to macrometastasis colonization                 Brain    ([@B78])

  PKCλ/i                            Migration, invasion                                                                            Activated by TGFβ/IL1β\                                                                        Golgi membrane, protein serine/threonine kinase activity                                            Intravasation, extravasation                           Lungs    ([@B79])
                                                                                                                                   Activates NFκB                                                                                                                                                                                                                                                     

  PML                               Migration, invasion                                                                            Activated by hypoxia/HIF1α signaling                                                           Response to hypoxia                                                                                 Intravasation, extravasation                           Lungs    ([@B80])

  POSTN                             Expressed by stromal or cancer cells\                                                          Activates Wnt1 and Wnt3A signaling\                                                            Negative regulation of cell--matrix adhesion, response to hypoxia                                   Micro- to macrometastasis colonization                 Lungs    ([@B81], [@B82])
                                    Promotes cancer stem cell maintenance                                                          Activates NFκB and Erk signaling                                                                                                                                                                                                                                   

  PTHLH                             Osteoclast activation                                                                          Activated by TGFβ signaling\                                                                   Osteoblast development, hormone activity                                                            Micro- to macrometastasis colonization                 Bone     ([@B83], [@B84])
                                                                                                                                   Induced by miR-218-5p                                                                                                                                                                                                                                              

  PTK6                              Promotes EMT *via* Snail upregulation                                                          Activates EGF and PI~3~K/Akt signaling                                                         Protein tyrosine kinase activity                                                                    Local invasion\                                        Lungs    ([@B85], [@B86])
                                                                                                                                                                                                                                                                                                                                      Intravasation                                                   

  RAD51                             Promotes aberrant DNA repair                                                                   Double-strand break repair pathway                                                             Double-strand break repair *via* homologous recombination                                           Intravasation, extravasation                           Lungs    ([@B87])

  RAGE                              Binds S100A7 to promote recruitment of tumor-associated macrophages and migration              Activates Erk and NFκB pathways                                                                Cytokine production, inflammatory responses                                                         Primary and metastatic tumor growth\                   Lungs    ([@B88])
                                                                                                                                                                                                                                                                                                                                      Intravasation, extravasation                                    

  RANKL                             Migration\                                                                                     Activates NFκB signaling\                                                                      Osteoblast proliferation, cytokine activity, monocyte chemotaxis                                    Intravasation, extravasation\                          Bone     ([@B84], [@B89])
                                    Osteoclast activation                                                                          Induced by miR-218-5p                                                                                                                                                                              Micro- to macrometastasis colonization                          

  S100A7                            Promotes inflammation, recruitment of tumor-associated macrophages and angiogenesis            Activates STAT3, Akt and Erk pathways                                                          Response to ROS, angiogenesis                                                                       Primary and metastatic tumor growth                    Lungs    ([@B90])

  SERPINS (NS, B2, D1)              Inhibit plasminogen activation\                                                                Inhibits FasL-mediated apoptotic pathway                                                       Serine-type endopeptidase inhibitor activity, chemotaxis, blood coagulation                         Survival\                                              Brain    ([@B91])
                                    Promote vascular co-option                                                                                                                                                                                                                                                                        Micro- to macrometastasis colonization                          

  SLUG                              Promotes EMT\                                                                                  Activated by Erk, FGF signaling\                                                               EMT                                                                                                 Local invasion\                                        Lungs    ([@B22], [@B92]--[@B94])
                                    Migration\                                                                                     Activates TGFβ signaling                                                                                                                                                                           Intravasation Metastatic colonization                           
                                    Invasion\                                                                                                                                                                                                                                                                                                                                                         
                                    Survival by suppressing Puma-induced apoptosis                                                                                                                                                                                                                                                                                                                    

  SNAIL                             Promotes EMT\                                                                                  Activated by EGF signaling\                                                                    EMT, Mesoderm formation                                                                             Local invasion\                                        Lungs    ([@B23], [@B94]--[@B96])
                                    Migration\                                                                                     Activates TGFβ signaling                                                                                                                                                                           Intravasation                                                   
                                    Invasion                                                                                                                                                                                                                                                                                                                                                          

  SPRY1                             Promotes EGFR stability\                                                                       Activates EGFR signaling                                                                       Mitotic spindle orientation                                                                         Intravasation, extravasation                           Lungs    ([@B97])
                                    Promotes EMT, migration, invasion                                                                                                                                                                                                                                                                                                                                 

  ST6GALNAC5                        Mediates brain infiltration across the blood--brain barrier                                    Catalyzes cell-surface sialylation                                                             Golgi membrane, sialytransferase activity                                                           Extravasation                                          Brain    ([@B98])

  TGFβ1                             EMT\                                                                                           Activates AP1- and Smad4-dependent interleukin-11 and CTGF expression.\                        EMT, vasculogenesis, neural tube closure, response to hypoxia                                       Intravasation, extravasation\                          Lungs\   ([@B26], [@B99], [@B100])
                                    Migration\                                                                                     Maintains Smad2-dependent, DNMT1 mediated DNA methylation and silencing of CDH1                                                                                                                    Colonization                                           Bone     
                                    Invasion\                                                                                                                                                                                                                                                                                                                                                         
                                    Promotes osteoclastic bone resorption                                                                                                                                                                                                                                                                                                                             

  TNC                               Promotes survival and outgrowth of macrometastases                                             Activates Notch and Wnt signaling                                                              Osteoblast differentiation, extracellular region                                                    Micro- to macrometastasis colonization                 Lungs    ([@B101])

  TRKB                              Suppresses anoikis to promote survival in circulation\                                         Interacts with brain-derived neurotrophic factor ligand\                                       Vasculogenesis, neuron migration                                                                    Survival in circulation                                Lungs\   ([@B48], [@B49])
                                    Modulates breast cancer-endothelial cell interaction                                           Activates Erk and PI~3~K signaling                                                                                                                                                                                                                        Bone     

  TWIST                             Promotes EMT\                                                                                  Induced by Wnt signaling                                                                       Neuron migration, neural tube closure, morphogenesis                                                Local invasion\                                        Lungs    ([@B24], [@B102])
                                    Migration\                                                                                                                                                                                                                                                                                        Intravasation                                                   
                                    Invasion                                                                                                                                                                                                                                                                                                                                                          

  VCAM1                             Osteoclast activation through interaction with integrin α4β1\                                  Activated by NFκB pathway\                                                                     Inflammatory response, integrin binding, extracellular space                                        Survival\                                              Bone\    ([@B60], [@B103], [@B104])
                                    Binds metastasis-associated macrophages via α4 integrins                                       Activates PI~3~K/Akt pathway                                                                                                                                                                       Micro- to macrometastasis colonization                 Lungs    

  WAVE3                             Promotes EMT                                                                                   Activates TGFβ signaling                                                                       Actin binding, cytoskeleton organization, lamellipodium                                             Intravasation, extravasation                           Lungs    ([@B27])

  Wnt1                              Maintains CSC renewal\                                                                         Activates Wnt/β-catenin signaling\                                                             Embryonic axis specification, frizzled binding, cytokine activity                                   Intravasation, extravasation\                          Lungs\   ([@B84], [@B105]--[@B107])
                                    Migration\                                                                                     Induced by miR-218-5p                                                                                                                                                                              Colonization                                           Bone     
                                    Invasion                                                                                                                                                                                                                                                                                                                                                          

  ΔNp63                             Promotes migration, invasion\                                                                  Activates PI3K signaling and CD44v6 expression                                                 Transcription factor activity, p53 binding                                                          Intravasation, extravasation                           Lungs\   ([@B108])
                                    EMT                                                                                                                                                                                                                                                                                                                                                      Bone     

  **Metastasis suppressor genes**                                                                                                                                                                                                                                                                                                                                                                     

  FOXF2                             Inhibits migration, invasion                                                                   Blocks EMT by suppressing Twist                                                                Transcription factor activity,\                                                                     Intravasation, extravasation                           Lungs    ([@B44])
                                                                                                                                                                                                                                  EMT                                                                                                                                                                 

  LIFR                              Inhibits migration, invasion                                                                   Targeted by miR-9\                                                                             Regulation of cytokine-mediated signaling pathway                                                   Intravasation, extravasation\                          Lungs    ([@B43])
                                                                                                                                   Activates Hippo/YAP pathway                                                                                                                                                                        Metastatic colonization                                         

  LOXL4                             Inhibits migration, invasion, primary and metastatic tumor growth                              Suppresses collagen synthesis                                                                  Scavenger receptor activity, oxidoreductase activity                                                Intravasation, extravasation                           Lungs    ([@B25])

  TP63                              Inhibits migration, invasion\                                                                  Inhibited by TGFβ-induced Smad/mutant-p53 complex\                                             Transcription factor activity, p53 binding                                                          Intravasation, extravasation                           Lungs    ([@B40]--[@B42])
                                    Regulates miRNA processing                                                                     Induced by IL13\                                                                                                                                                                                                                                                   
                                                                                                                                   Upregulates Dicer to control miRNA processing                                                                                                                                                                                                                      

  RAB1B                             Inhibits migration, invasion                                                                   Activates TGFβ/Smad signaling                                                                  Golgi membrane                                                                                      Intravasation, extravasation                           Lungs    ([@B46])

  SDPR                              Inhibits extravasation, Apoptosis                                                              Silenced by DNA methylation\                                                                   Phosphatidylserine binding                                                                          Extravasation\                                         Lungs    ([@B109])
                                                                                                                                   Suppresses NFκB, Erk                                                                                                                                                                               Apoptosis at secondary organ                                    

  SHARP1                            Promotes degradation of hypoxia-inducible factors\                                             Suppresses hypoxia-inducible pathway                                                           DNA binding transcription factor activity                                                           Extravasation                                          Lungs    ([@B110])
                                    Inhibits migration, invasion                                                                                                                                                                                                                                                                                                                                      

  SSBP1                             Inhibits TGFβ-induced EMT                                                                      Regulates mitochondrial retrograde signaling                                                   Single-stranded DNA binding, RNA binding, mitochondrial matrix                                      Intravasation, extravasation                           Lungs    ([@B45])

  TIEG1                             Inhibits migration, invasion                                                                   Downregulates EGFR expression to suppress EGF signaling                                        DNA binding transcription factor activity                                                           Intravasation, extravasation                           Lungs    ([@B47])

  TXNIP                             Blocks glucose uptake and aerobic glycolysis\                                                  Suppressed by Myc oncogene and miR-373                                                         Mitochondrial intermembrane space, enzyme inhibitor activity                                        Intravasation, extravasation\                          Lungs    ([@B111], [@B112])
                                    Suppresses EMT                                                                                                                                                                                                                                                                                    Metastatic colonization and growth                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*A comprehensive list of genes implicated in various stages of the metastatic cascade, their reported functions, upstream or downstream regulatory signaling pathways involved, gene ontology, as well as the secondary organs which become affected*.

Metastatic Colonization {#S3-4}
-----------------------

Following extravasation and infiltration at the secondary site, a genetic program is initiated so that cancer cells can escape dormancy and form micro and macrometastatic tumors. Initially, EMT plasticity and the reversal to MET phenotype have been shown to be important for metastatic colonization ([@B113]). During this process, epithelial phenotype becomes re-established through miR-200-mediated downregulation of ZEB1, SIP1 to promote metastatic colonization ([@B114], [@B115]). Also, breast DTCs in the bone marrow gain the ability to form typical osteolytic metastases by producing parathyroid hormone-related protein (PTHLH), tumor necrosis factor-α (TNFα), interleukin-6 and/or interleukin-11. These factors stimulate the release of receptor activator of nuclear factor-κB ligand (RANKL) from osteoblasts which induces osteoclast formation ([@B33], [@B58], [@B83], [@B116]). Furthermore, inflammation in the lung microenvironment could also be responsible for triggering the escape of metastatic breast cancer cells from latency leading to metastatic colonization ([@B117]). A subset of genes contributing to primary tumor growth can also promote survival and growth at the secondary site. Chemokines CXCL1/2 mediate chemoresistance and lung metastasis by attracting myeloid cells into the tumor, which produce low molecular weight calcium-binding proteins S100A8/9 that enhance cancer cell survival by binding to the receptor for advanced glycation end products (RAGE) ([@B59]). Another calcium binding protein, S100A7 has been found to enhance tumor growth and metastasis, by binding to RAGE and activating Erk and NFκB signaling ([@B88], [@B90]). Furthermore, fibroblast growth factor receptor (FGFR) was shown to trigger pro-survival signals through PI~3~K/Akt signaling and promote outgrowth of metastatic breast cancer cells to the lungs ([@B62]). However, it needs to be highlighted that cellular and genetic context among cancers influences whether proteins act as tumor suppressors or metastasis promoters. One controversial example is LOXL4 which has been shown to recruit bone marrow-derived cells and facilitate colonization of TNBC to the lungs *via* a HIF1α-dependent mechanism ([@B118]). However, in another study, knockdown of LOXL4 expression in TNBC cells promoted primary tumor growth and lung metastasis which was associated with thickening of collagen bundles and remodeling of the extracellular matrix (ECM) within tumors ([@B25]). Overall, it is noteworthy that while some genes have been associated only with TNBC metastasis so far (i.e., TIEG1, MAFK, MLK3, SDPR), the majority is also involved in other tumor types, suggesting a more fundamental role in cancer progression.

Concluding Remarks on Current and Future Perspectives on TNBC Metastasis Therapy {#S4}
================================================================================

Due to their molecular heterogeneity, there are no drugs that can target the entire spectrum of TNBC tumors and each subtype is vulnerable to specific therapeutic approaches. Despite the lack of FDA-approved targeted therapies for TNBC to date, ongoing clinical trials are assessing the efficacy of single or combinatorial approaches that tackle different TNBC molecular alterations. Up to 20% of TNBC have been associated with germ-line mutations in BRCA1 ([@B119]). TNBC tumors with loss of function of BRCA1 or BRCA2 are sensitive to poly(ADP-ribose) polymerase inhibitors and alkylating agents that induce DNA double-strand breaks ([@B120]). Olaparib has been the most successful PARP inhibitor against BRCA-mutated TNBC, inducing partial responses in 54% of patients when administered as a single agent ([@B121]) and an overall response rate of 88% when combined with carboplatin ([@B122]). Anti-androgens as well as FGFR inhibitors have been tested in clinical trials against TNBCs that are androgen receptor-positive or harbor FGFR amplification, respectively ([@B123], [@B124]). Gamma-secretase inhibitors that block the NOTCH pathway are currently in clinical trials for TNBC patients with upregulated NOTCH signaling ([@B125]). All together clinical trials have shown that each agent alone provides small or no benefit in TNBC patients suggesting that further effort is needed to discover novel targets of TNBC and to identify each patient's molecular profile that will lead to a more individualized treatment.

Toward this goal, some of the metastasis-promoting genes reported here could be further exploited for the future development of promising targeted therapies. Since local invasion, intravasation and possibly extravasation are thought to occur relatively early in the metastatic process ([@B32]), a plausible strategy would be to target dormancy and the outgrowth of macrometastatic tumors in distal organs. Since this final stage is considered the critical "rate-limiting" step of the "invasion-metastasis" cascade requiring even years to be completed, it provides a window of opportunity for effective therapy. Therefore, different approaches could aim against "druggable" molecules that facilitate metastatic colonization, such as overexpressed receptors or secreted molecules (i.e., CXCL1/2, FGFR, TGFβ1, WNT1, ANGPTL2, CSF2, RANKL), which target commonly deregulated signaling networks at this late-stage (Table [1](#T1){ref-type="table"}). Ongoing clinical trials are evaluating the efficacy of the TGFβR1 inhibitor LY2157299 with paclitaxel (NCT02672475), whereas the FGFR inhibitor Lucitanib is also under testing (NCT02202746) for patients with metastatic TNBC. The ultimate goal would be, if not to completely eliminate dormant metastatic breast cancer cells, to prolong dormancy period and hopefully transform this stage into a chronic inactive cancer cell state.

Importantly, recent studies have shown that tumor cells are able to evade immune responses by activating negative regulatory pathways, also known as immune checkpoints, that block T-cell activation through cytotoxic T-lymphocyte protein 4 (CTLA4) or *via* binding of the programmed cell death protein 1 (PD1) receptor expressed on T-cell surface to the PDL1 ligand expressed by cancer cells in response to various cytokines ([@B126]). The recent development and FDA approval of anti-CTLA4, anti-PDL1, and anti-PDL1 monoclonal antibodies that elicit antitumor clinical responses in a variety of solid cancers created enthusiasm for cancer therapy ([@B127]). Currently, several clinical trials are underway to evaluate the efficacy of this approach in TNBC as well ([@B128]).

However, a major clinical problem is that breast cancer is considered one of the most desmoplastic tumor types due to the production of excessive amounts of ECM components, such as collagen and hyaluronan, which generate mechanical stresses within the growing tumor ([@B129]). This results in blood vessel compression, hypoperfusion, and hypoxia which promote cancer progression and metastasis as well as hinder drug delivery ([@B130]). Therefore, targeting components of the tumor microenvironment has also been recently proposed as another promising strategy for TNBC therapy by improving tumor penetration and delivery of cytotoxic drugs ([@B131]). For example, targeting of cancer-associated fibroblasts using pirfenidone, an FDA-approved drug for idiopathic pulmonary fibrosis, has been shown to suppress metastasis of TNBC in combination with doxorubicin ([@B132]). This effect is likely to be mediated through remodeling of tumor microenvironment which reduces ECM components through suppression of TGFβ signaling, improves perfusion and delivery of chemotherapy ([@B133]). Similar effects have also been demonstrated using the anti-fibrotic drug Tranilast or the anti-hypertensive drug Losartan in combination with chemotherapy or nanotherapy in mouse models for TNBC ([@B134]--[@B136]).

In conclusion, this evidence suggests that efforts in the near future should be focused toward the development and testing of novel anti-metastatic targeted therapies for late-stage TNBC that could be used in combination with existing chemotherapies, immunotherapies as well as with microenvironment-remodeling agents that can improve drug penetration and overall therapeutic efficacy.
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